CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

Primary effusion lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma characterized by short survival with current therapies, emphasizing the urgent need to develop new therapeutic approaches. Brentuximab vedotin (SGN-35) is an anti-CD30 monoclonal antibody (cAC10) conjugated by a proteas...

Full description

Saved in:
Bibliographic Details
Main Authors: Bhatt, Shruti, Ashlock, Brittany M., Natkunam, Yasodha, Sujoy, Victoria, Chapman, Jennifer Rose, Ramos, Juan Carlos, Mesri, Enrique A., Lossos, Izidore S.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2013
Subjects:
Lymphoid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3744990/
https://ncbi.nlm.nih.gov/pubmed/23838350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-01-481713
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items